Advertisement

Neuroscience Bulletin

, Volume 30, Issue 2, pp 295–307 | Cite as

M1 muscarinic acetylcholine receptor in Alzheimer’s disease

  • Shangtong Jiang
  • Yanfang Li
  • Cuilin Zhang
  • Yingjun Zhao
  • Guojun Bu
  • Huaxi Xu
  • Yun-Wu ZhangEmail author
Review

Abstract

The degeneration of cholinergic neurons and cholinergic hypofunction are pathologies associated with Alzheimer’s disease (AD). Muscarinic acetylcholine receptors (mAChRs) mediate acetylcholine-induced neurotransmission and five mAChR subtypes (M1–M5) have been identified. Among them, M1 mAChR is widely expressed in the central nervous system and has been implicated in many physiological and pathological brain functions. In addition, M1 mAChR is postulated to be an important therapeutic target for AD and several other neurodegenerative diseases. In this article, we review recent progress in understanding the functional involvement of M1 mAChR in AD pathology and in developing M1 mAChR agonists for AD treatment.

Keywords

agonist Alzheimer’s disease amyloid cholinergic hypofunction M1 muscarinic acetylcholine receptor tau 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Richter JA, Perry EK, Tomlinson BE. Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer’s disease. Life Sci 1980, 26: 1683–1689.PubMedGoogle Scholar
  2. [2]
    Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982, 215: 1237–1239.PubMedGoogle Scholar
  3. [3]
    Pakaski M, Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimer’s disease. Neurochem Int 2008, 53: 103–111.PubMedGoogle Scholar
  4. [4]
    Tanzi RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell 2005, 120: 545–555.PubMedGoogle Scholar
  5. [5]
    Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992, 256: 184–185.PubMedGoogle Scholar
  6. [6]
    Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer’s disease: synapses gone cold. Mol Neurodegener 2011, 6: 63.PubMedCentralPubMedGoogle Scholar
  7. [7]
    Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001, 81: 741–766.PubMedGoogle Scholar
  8. [8]
    Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000, 33: 95–130.PubMedGoogle Scholar
  9. [9]
    Iqbal K, Alonso AD, Gondal JA, Gong CX, Haque N, Khatoon S, et al. Mechanism of neurofibrillary degeneration and pharmacologic therapeutic approach. J Neural Transm Suppl 2000, 59: 213–222.PubMedGoogle Scholar
  10. [10]
    Mudher A, Lovestone S. Alzheimer’s disease-do tauists and baptists finally shake hands? Trends Neurosci 2002, 25: 22–26.PubMedGoogle Scholar
  11. [11]
    Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet 2006, 368: 387–403.PubMedGoogle Scholar
  12. [12]
    Salloway S, Mintzer J, Weiner MF, Cummings JL. Diseasemodifying therapies in Alzheimer’s disease. Alzheimers Dement 2008, 4: 65–79.PubMedGoogle Scholar
  13. [13]
    Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006: CD005593.Google Scholar
  14. [14]
    Ringman JM, Cummings JL. Current and emerging pharmacological treatment options for dementia. Behav Neurol 2006, 17: 5–16.PubMedGoogle Scholar
  15. [15]
    Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000, 163: 495–529.PubMedGoogle Scholar
  16. [16]
    Geula C, Nagykery N, Nicholas A, Wu CK. Cholinergic neuronal and axonal abnormalities are present early in aging and in Alzheimer disease. J Neuropathol Exp Neurol 2008, 67: 309–318.PubMedCentralPubMedGoogle Scholar
  17. [17]
    Ladner CJ, Lee JM. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 1998, 57: 719–731.PubMedGoogle Scholar
  18. [18]
    Perry E, Court J, Goodchild R, Griffiths M, Jaros E, Johnson M, et al. Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm 1998, 105: 915–933.PubMedGoogle Scholar
  19. [19]
    Chen GJ, Xiong Z, Yan Z. Abeta impairs nicotinic regulation of inhibitory synaptic transmission and interneuron excitability in prefrontal cortex. Mol Neurodegener 2013, 8: 3.PubMedCentralPubMedGoogle Scholar
  20. [20]
    Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease. J Neurochem 2012, 120Suppl 1: 22–33.PubMedGoogle Scholar
  21. [21]
    Nathanson NM. Molecular properties of the muscarinic acetylcholine receptor. Annu Rev Neurosci 1987, 10: 195–236.PubMedGoogle Scholar
  22. [22]
    Caulfield MP. Muscarinic receptors—characterization, coupling and function. Pharmacol Ther 1993, 58: 319–379.PubMedGoogle Scholar
  23. [23]
    Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 1996, 10: 69–99.PubMedGoogle Scholar
  24. [24]
    Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987, 237: 527–532.PubMedGoogle Scholar
  25. [25]
    Bonner TI, Young AC, Brann MR, Buckley NJ. Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1988, 1: 403–410.PubMedGoogle Scholar
  26. [26]
    Felder CC, Bymaster FP, Ward J, DeLapp N. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 2000, 43: 4333–4353.PubMedGoogle Scholar
  27. [27]
    Hulme EC, Lu ZL, Saldanha JW, Bee MS. Structure and activation of muscarinic acetylcholine receptors. Biochem Soc Trans 2003, 31: 29–34.PubMedGoogle Scholar
  28. [28]
    Wess J. Allosteric binding sites on muscarinic acetylcholine receptors. Mol Pharmacol 2005, 68: 1506–1509.PubMedGoogle Scholar
  29. [29]
    Presland J. Identifying novel modulators of G proteincoupled receptors via interaction at allosteric sites. Curr Opin Drug Discov Devel 2005, 8: 567–576.PubMedGoogle Scholar
  30. [30]
    Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 2009, 8: 41–54.PubMedCentralPubMedGoogle Scholar
  31. [31]
    Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006, 16: 710–715.PubMedCentralPubMedGoogle Scholar
  32. [32]
    Briand LA, Gritton H, Howe WM, Young DA, Sarter M. Modulators in concert for cognition: modulator interactions in the prefrontal cortex. Prog Neurobiol 2007, 83: 69–91.PubMedCentralPubMedGoogle Scholar
  33. [33]
    Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 2007, 6: 721–733.PubMedGoogle Scholar
  34. [34]
    Bymaster FP, McKinzie DL, Felder CC, Wess J. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 2003, 28: 437–442.PubMedGoogle Scholar
  35. [35]
    Birdsall NJ, Farries T, Gharagozloo P, Kobayashi S, Lazareno S, Sugimoto M. Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies. Mol Pharmacol 1999, 55: 778–786.PubMedGoogle Scholar
  36. [36]
    Hamilton SE, Loose MD, Qi M, Levey AI, Hille B, McKnight GS, et al. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc Natl Acad Sci U S A 1997, 94: 13311–13316.PubMedCentralPubMedGoogle Scholar
  37. [37]
    Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A 2001, 98: 15312–15317.PubMedCentralPubMedGoogle Scholar
  38. [38]
    Miyakawa T, Yamada M, Duttaroy A, Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. J Neurosci 2001, 21: 5239–5250.PubMedGoogle Scholar
  39. [39]
    VanDeMark KL, Guizzetti M, Giordano G, Costa LG. The activation of M1 muscarinic receptor signaling induces neuronal differentiation in pyramidal hippocampal neurons. J Pharmacol Exp Ther 2009, 329: 532–542.PubMedCentralPubMedGoogle Scholar
  40. [40]
    Hohmann CF, Potter ED, Levey AI. Development of muscarinic receptor subtypes in the forebrain of the mouse. J Comp Neurol 1995, 358: 88–101.PubMedGoogle Scholar
  41. [41]
    Shideler KK, Yan J. M1 muscarinic receptor for the development of auditory cortical function. Mol Brain 2010, 3: 29.PubMedCentralPubMedGoogle Scholar
  42. [42]
    Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003, 6: 51–58.PubMedGoogle Scholar
  43. [43]
    Shinoe T, Matsui M, Taketo MM, Manabe T. Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J Neurosci 2005, 25: 11194–11200.PubMedGoogle Scholar
  44. [44]
    Wess J. Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 2004, 44: 423–450.PubMedGoogle Scholar
  45. [45]
    Mrzljak L, Levey AI, Goldman-Rakic PS. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. Proc Natl Acad Sci U S A 1993, 90: 5194–5198.PubMedCentralPubMedGoogle Scholar
  46. [46]
    Levey AI. Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. Proc Natl Acad Sci U S A 1996, 93: 13541–13546.PubMedCentralPubMedGoogle Scholar
  47. [47]
    Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993, 52: 441–448.PubMedGoogle Scholar
  48. [48]
    Hersch SM, Gutekunst CA, Rees HD, Heilman CJ, Levey AI. Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 1994, 14: 3351–3363.PubMedGoogle Scholar
  49. [49]
    Chen SR, Wess J, Pan HL. Functional activity of the M2 and M4 receptor subtypes in the spinal cord studied with muscarinic acetylcholine receptor knockout mice. J Pharmacol Exp Ther 2005, 313: 765–770.PubMedGoogle Scholar
  50. [50]
    Gautam D, Jeon J, Li JH, Han SJ, Hamdan FF, Cui Y, et al. Metabolic roles of the M3 muscarinic acetylcholine receptor studied with M3 receptor mutant mice: a review. J Recept Signal Transduct Res 2008, 28: 93–108.PubMedGoogle Scholar
  51. [51]
    Gautam D, Jeon J, Starost MF, Han SJ, Hamdan FF, Cui Y, et al. Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth. Proc Natl Acad Sci U S A 2009, 106: 6398–6403.PubMedCentralPubMedGoogle Scholar
  52. [52]
    Trendelenburg AU, Gomeza J, Klebroff W, Zhou H, Wess J. Heterogeneity of presynaptic muscarinic receptors mediating inhibition of sympathetic transmitter release: a study with M2- and M4-receptor-deficient mice. Br J Pharmacol 2003, 138: 469–480.PubMedCentralPubMedGoogle Scholar
  53. [53]
    Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 2003, 9: 159–186.PubMedGoogle Scholar
  54. [54]
    Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, et al. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A 2008, 105: 10978–10983.PubMedCentralPubMedGoogle Scholar
  55. [55]
    Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, et al. Enhancement of D1 dopamine receptormediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 1999, 96: 10483–10488.PubMedCentralPubMedGoogle Scholar
  56. [56]
    Bohme TM, Augelli-Szafran CE, Hallak H, Pugsley T, Serpa K, Schwarz RD. Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors. J Med Chem 2002, 45: 3094–3102.PubMedGoogle Scholar
  57. [57]
    Eglen RM, Nahorski SR. The muscarinic M(5) receptor: a silent or emerging subtype? Br J Pharmacol 2000, 130: 13–21.PubMedCentralPubMedGoogle Scholar
  58. [58]
    Fink-Jensen A, Fedorova I, Wortwein G, Woldbye DP, Rasmussen T, Thomsen M, et al. Role for M5 muscarinic acetylcholine receptors in cocaine addiction. J Neurosci Res 2003, 74: 91–96.PubMedGoogle Scholar
  59. [59]
    Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 2011, 6: 27.PubMedCentralPubMedGoogle Scholar
  60. [60]
    Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer’s disease. Mol Brain 2011, 4: 3.PubMedCentralPubMedGoogle Scholar
  61. [61]
    Haring R, Gurwitz D, Barg J, Pinkas-Kramarski R, Heldman E, Pittel Z, et al. Amyloid precursor protein secretion via muscarinic receptors: reduced desensitization using the M1-selective agonist AF102B. Biochem Biophys Res Commun 1994, 203: 652–658.PubMedGoogle Scholar
  62. [62]
    Haring R, Gurwitz D, Barg J, Pinkas-Kramarski R, Heldman E, Pittel Z, et al. NGF promotes amyloid precursor protein secretion via muscarinic receptor activation. Biochem Biophys Res Commun 1995, 213: 15–23.PubMedGoogle Scholar
  63. [63]
    Eckols K, Bymaster FP, Mitch CH, Shannon HE, Ward JS, DeLapp NW. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci 1995, 57: 1183–1190.PubMedGoogle Scholar
  64. [64]
    Farber SA, Nitsch RM, Schulz JG, Wurtman RJ. Regulated secretion of beta-amyloid precursor protein in rat brain. J Neurosci 1995, 15: 7442–7451.PubMedGoogle Scholar
  65. [65]
    Muller DM, Mendla K, Farber SA, Nitsch RM. Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain. Life Sci 1997, 60: 985–991.PubMedGoogle Scholar
  66. [66]
    Pittel Z, Heldman E, Barg J, Haring R, Fisher A. Muscarinic control of amyloid precursor protein secretion in rat cerebral cortex and cerebellum. Brain Res 1996, 742: 299–304.PubMedGoogle Scholar
  67. [67]
    Haring R, Fisher A, Marciano D, Pittel Z, Kloog Y, Zuckerman A, et al. Mitogen-activated protein kinasedependent and protein kinase C-dependent pathways link the m1 muscarinic receptor to beta-amyloid precursor protein secretion. J Neurochem 1998, 71: 2094–2103.PubMedGoogle Scholar
  68. [68]
    Hung AY, Haass C, Nitsch RM, Qiu WQ, Citron M, Wurtman RJ, et al. Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J Biol Chem 1993, 268: 22959–22962.PubMedGoogle Scholar
  69. [69]
    Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992, 258: 304–307.PubMedGoogle Scholar
  70. [70]
    Wolf BA, Wertkin AM, Jolly YC, Yasuda RP, Wolfe BB, Konrad RJ, et al. Muscarinic regulation of Alzheimer’s disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 1995, 270: 4916–4922.PubMedGoogle Scholar
  71. [71]
    Cisse M, Braun U, Leitges M, Fisher A, Pages G, Checler F, et al. ERK1-independent alpha-secretase cut of betaamyloid precursor protein via M1 muscarinic receptors and PKCalpha/epsilon. Mol Cell Neurosci 2011, 47: 223–232.PubMedGoogle Scholar
  72. [72]
    Xu H, Greengard P, Gandy S. Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. J Biol Chem 1995, 270: 23243–23245.PubMedGoogle Scholar
  73. [73]
    Bigl V, Rossner S. Amyloid precursor protein processing in vivo—insights from a chemically-induced constitutive overactivation of protein kinase C in Guinea pig brain. Curr Med Chem 2003, 10: 871–882.PubMedGoogle Scholar
  74. [74]
    Davis AA, Fritz JJ, Wess J, Lah JJ, Levey AI. Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J Neurosci 2010, 30: 4190–4196.PubMedCentralPubMedGoogle Scholar
  75. [75]
    Chami L, Checler F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer’s disease. Mol Neurodegener 2012, 7: 52.PubMedCentralPubMedGoogle Scholar
  76. [76]
    Cole SL, Vassar R. The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol Neurodegener 2007, 2: 22.PubMedCentralPubMedGoogle Scholar
  77. [77]
    Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006, 49: 671–682.PubMedGoogle Scholar
  78. [78]
    Zuchner T, Perez-Polo JR, Schliebs R. Beta-secretase BACE1 is differentially controlled through muscarinic acetylcholine receptor signaling. J Neurosci Res 2004, 77: 250–257.PubMedGoogle Scholar
  79. [79]
    Jiang S, Wang Y, Ma Q, Zhou A, Zhang X, Zhang YW. M1 muscarinic acetylcholine receptor interacts with BACE1 and regulates its proteosomal degradation. Neurosci Lett 2012, 515: 125–130.PubMedGoogle Scholar
  80. [80]
    Farias GG, Godoy JA, Hernandez F, Avila J, Fisher A, Inestrosa NC. M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol Dis 2004, 17: 337–348.PubMedGoogle Scholar
  81. [81]
    Sadot E, Gurwitz D, Barg J, Behar L, Ginzburg I, Fisher A. Activation of m1 muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells. J Neurochem 1996, 66: 877–880.PubMedGoogle Scholar
  82. [82]
    Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm 2000, 107: 1201–1212.PubMedGoogle Scholar
  83. [83]
    De Sarno P, Shestopal SA, King TD, Zmijewska A, Song L, Jope RS. Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition. J Biol Chem 2003, 278: 11086–11093.PubMedCentralPubMedGoogle Scholar
  84. [84]
    Leloup C, Michaelson DM, Fisher A, Hartmann T, Beyreuther K, Stein R. M1 muscarinic receptors block caspase activation by phosphoinositide 3-kinase- and MAPK/ERK-independent pathways. Cell Death Differ 2000, 7: 825–833.PubMedGoogle Scholar
  85. [85]
    Hanyu H, Shimizu T, Tanaka Y, Takasaki M, Koizumi K, Abe K. Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2003, 15: 177–182.PubMedGoogle Scholar
  86. [86]
    Bateman GA, Levi CR, Schofield P, Wang Y, Lovett EC. Quantitative measurement of cerebral haemodynamics in early vascular dementia and Alzheimer’s disease. J Clin Neurosci 2006, 13: 563–568.PubMedGoogle Scholar
  87. [87]
    Uslaner JM, Eddins D, Puri V, Cannon CE, Sutcliffe J, Chew CS, et al. The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque. Psychopharmacology (Berl) 2013, 225: 21–30.Google Scholar
  88. [88]
    Svensson AL, Alafuzoff I, Nordberg A. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. Brain Res 1992, 596: 142–148.PubMedGoogle Scholar
  89. [89]
    Mulugeta E, Karlsson E, Islam A, Kalaria R, Mangat H, Winblad B, et al. Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 2003, 960: 259–262.PubMedGoogle Scholar
  90. [90]
    Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 2004, 145: 59–66.PubMedGoogle Scholar
  91. [91]
    Ferrari-DiLeo G, Mash DC, Flynn DD. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol Chem Neuropathol 1995, 24: 69–91.PubMedGoogle Scholar
  92. [92]
    Tsang SW, Lai MK, Kirvell S, Francis PT, Esiri MM, Hope T, et al. Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer’s disease. Neurobiol Aging 2006, 27: 1216–1223.PubMedGoogle Scholar
  93. [93]
    Potter PE, Rauschkolb PK, Pandya Y, Sue LI, Sabbagh MN, Walker DG, et al. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease. Acta Neuropathol 2011, 122: 49–60.PubMedCentralPubMedGoogle Scholar
  94. [94]
    Ladner CJ, Lee JM. Reduced high-affinity agonist binding at the M(1) muscarinic receptor in Alzheimer’s disease brain: differential sensitivity to agonists and divalent cations. Exp Neurol 1999, 158: 451–458.PubMedGoogle Scholar
  95. [95]
    Shiozaki K, Iseki E. Decrease in GTP-sensitive high affinity agonist binding of muscarinic acetylcholine receptors in autopsied brains of dementia with Lewy bodies and Alzheimer’s disease. J Neurol Sci 2004, 223: 145–148.PubMedGoogle Scholar
  96. [96]
    Kelly JF, Furukawa K, Barger SW, Rengen MR, Mark RJ, Blanc EM, et al. Amyloid beta-peptide disrupts carbacholinduced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci U S A 1996, 93: 6753–6758.PubMedCentralPubMedGoogle Scholar
  97. [97]
    Janickova H, Rudajev V, Zimcik P, Jakubik J, Tanila H, El-Fakahany EE, et al. Uncoupling of M1 muscarinic receptor/G-protein interaction by amyloid beta(1–42). Neuropharmacology 2013, 67: 272–283.PubMedGoogle Scholar
  98. [98]
    Fisher A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease. Neurotherapeutics 2008, 5: 433–442.PubMedGoogle Scholar
  99. [99]
    Fisher A. Therapeutic strategies in Alzheimer’s disease: M1 muscarinic agonists. Jpn J Pharmacol 2000, 84: 101–112.PubMedGoogle Scholar
  100. [100]
    Eglen RM, Choppin A, Watson N. Therapeutic opportunities from muscarinic receptor research. Trends Pharmacol Sci 2001, 22: 409–414.PubMedGoogle Scholar
  101. [101]
    Clader JW, Wang Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer’s disease. Curr Pharm Des 2005, 11: 3353–3361.PubMedGoogle Scholar
  102. [102]
    Bartolomeo AC, Morris H, Buccafusco JJ, Kille N, Rosenzweig-Lipson S, Husbands MG, et al. The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist. J Pharmacol Exp Ther 2000, 292: 584–596.PubMedGoogle Scholar
  103. [103]
    Cui YH, Si W, Yin L, An SM, Jin J, Deng SN, et al. A novel derivative of xanomeline improved memory function in aged mice. Neurosci Bull 2008, 24: 251–257.PubMedGoogle Scholar
  104. [104]
    Si W, Zhang X, Niu Y, Yu H, Lei X, Chen H, et al. A novel derivative of xanomeline improves fear cognition in aged mice. Neurosci Lett 2010, 473: 115–119.PubMedGoogle Scholar
  105. [105]
    Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997, 54: 465–473.PubMedGoogle Scholar
  106. [106]
    Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, et al. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 1997, 11Suppl 4: S16–22.PubMedGoogle Scholar
  107. [107]
    Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 2008, 117: 232–243.PubMedGoogle Scholar
  108. [108]
    Beach TG, Walker DG, Potter PE, Sue LI, Fisher A. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. Brain Res 2001, 905: 220–223.PubMedGoogle Scholar
  109. [109]
    Fisher A. M1 muscarinic agonists target major hallmarks of Alzheimer’s disease—the pivotal role of brain M1 receptors. Neurodegener Dis 2008, 5: 237–240.PubMedGoogle Scholar
  110. [110]
    Digby GJ, Shirey JK, Conn PJ. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders. Mol Biosyst 2010, 6: 1345–1354.PubMedGoogle Scholar
  111. [111]
    Hock C, Maddalena A, Raschig A, Muller-Spahn F, Eschweiler G, Hager K, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer’s disease. Amyloid 2003, 10: 1–6.PubMedGoogle Scholar
  112. [112]
    Sullivan NR, Leventhal L, Harrison J, Smith VA, Cummons TA, Spangler TB, et al. Pharmacological characterization of the muscarinic agonist (3R,4R)-3-(3-hexylsulfanyl-pyrazin-2-yloxy)-1-aza-bicyclo[2.2.1]heptane (WAY-132983) in in vitro and in vivo models of chronic pain. J Pharmacol Exp Ther 2007, 322: 1294–1304.PubMedGoogle Scholar
  113. [113]
    Jakubik J, Bacakova L, El-Fakahany EE, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997, 52: 172–179.PubMedGoogle Scholar
  114. [114]
    Lazareno S, Birdsall B, Fukazawa T, Gharagozloo P, Hashimoto T, Kuwano H, et al. Allosteric effects of four stereoisomers of a fused indole ring system with 3H-Nmethylscopolamine and acetylcholine at M1–M4 muscarinic receptors. Life Sci 1999, 64: 519–526.PubMedGoogle Scholar
  115. [115]
    Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, et al. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 2009, 75: 577–588.PubMedCentralPubMedGoogle Scholar
  116. [116]
    Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, et al. Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci U S A 2009, 106: 15950–15955.PubMedCentralPubMedGoogle Scholar
  117. [117]
    Shirey JK, Brady AE, Jones PJ, Davis AA, Bridges TM, Kennedy JP, et al. A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning. J Neurosci 2009, 29: 14271–14286.PubMedCentralPubMedGoogle Scholar
  118. [118]
    Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, et al. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol Pharmacol 2006, 70: 1974–1983.PubMedGoogle Scholar
  119. [119]
    Langmead CJ, Fry VA, Forbes IT, Branch CL, Christopoulos A, Wood MD, et al. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol Pharmacol 2006, 69: 236–246.PubMedGoogle Scholar
  120. [120]
    Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 2008, 28: 10422–10433.PubMedCentralPubMedGoogle Scholar
  121. [121]
    Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH, et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol 2008, 154: 1104–1115.PubMedCentralPubMedGoogle Scholar
  122. [122]
    Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, et al. AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model. Neuropharmacology 2010, 58: 365–373.PubMedGoogle Scholar
  123. [123]
    Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, et al. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci 2010, 1: 104–121.PubMedCentralPubMedGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Shangtong Jiang
    • 1
    • 2
  • Yanfang Li
    • 1
  • Cuilin Zhang
    • 1
  • Yingjun Zhao
    • 3
  • Guojun Bu
    • 1
  • Huaxi Xu
    • 1
    • 3
  • Yun-Wu Zhang
    • 1
    Email author
  1. 1.Fujian Provincial Key Laboratory of Neurodegenerative Disease and Aging Research, Institute of Neuroscience, College of MedicineXiamen UniversityXiamenChina
  2. 2.School of Pharmaceutical SciencesXiamen UniversityXiamenChina
  3. 3.Degenerative Disease Research ProgramSanford-Burnham Medical Research InstituteLa JollaUSA

Personalised recommendations